Tempest Therapeutics, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Harding. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Harding has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TTOO / T2 Biosystems, Inc. Chief Commercial Officer 35,000
US:OVAS / Ovascience Inc. Chief Commercial Officer 2,290
US:HOLX / Hologic, Inc. Group VP & GM, Women's Health 29,137
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Harding. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TPST / Tempest Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TPST / Tempest Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2014-04-10 OVAS Harding David 1,000 32.2300 1,000 32.2300 32,230 731

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TPST / Tempest Therapeutics, Inc. Insider Trades
Insider Sales TPST / Tempest Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TPST / Tempest Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TPST / Tempest Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Harding as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2017-02-13 2017-02-09 4 TTOO T2 Biosystems, Inc.
Stock Option (Right to Buy)
A - Award 35,000 35,000
2017-02-13 2017-02-09 4 TTOO T2 Biosystems, Inc.
Restricted Stock Units
A - Award 17,500 17,500
2015-11-09 2015-10-30 4 TTOO T2 Biosystems, Inc.
Stock Option (Right to Buy)
A - Award 146,600 146,600
2015-11-09 3 TTOO T2 Biosystems, Inc.
Common Stock
2,000
2015-11-09 3 TTOO T2 Biosystems, Inc.
Common Stock
2,000
2015-04-14 2014-04-10 4 OVAS OvaScience, Inc.
Common Stock
P - Purchase 1,000 2,290 77.52 32.23 32,230 73,807
2014-12-11 2014-12-09 4 OVAS OvaScience, Inc.
Stock Option (right to buy)
A - Award 343,000 343,000
2013-11-20 2013-11-18 4 HOLX HOLOGIC INC
Performance Stock Unit Award (Right to Receive)
A - Award 29,137 29,137
2013-11-20 2013-11-18 4 HOLX HOLOGIC INC
Restricted Stock Unit Award (Right To Receive)
A - Award 14,568 14,568
2013-11-20 2013-11-18 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
A - Award 41,565 41,565
2013-11-18 2013-11-14 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -975 53,645 -1.79 21.11 -20,582 1,132,446
2013-11-12 2013-11-11 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -421 54,620 -0.76 22.90 -9,640 1,250,743
2013-11-12 2013-11-08 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -449 55,041 -0.81 22.04 -9,896 1,213,104
2013-11-12 2013-11-08 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -454 55,490 -0.81 22.04 -10,006 1,223,000
2013-07-01 2013-06-28 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -10,866 55,944 -16.26 19.30 -209,714 1,079,719
2012-11-15 2012-11-14 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
A - Award 33,309 33,309 19.86 661,517 661,517
2012-11-15 2012-11-14 4 HOLX HOLOGIC INC
Common Stock
A - Award 11,958 66,810 21.80
2012-11-15 2012-11-13 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -1,031 54,852 -1.84 20.25 -20,878 1,110,753
2012-11-13 2012-11-11 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -409 55,883 -0.73 20.32 -8,311 1,135,543
2012-11-13 2012-11-10 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -436 56,292 -0.77 20.32 -8,860 1,143,853
2012-11-13 2012-11-09 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -441 56,728 -0.77 20.32 -8,961 1,152,713
2012-09-10 2012-09-07 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
M - Exercise -7,800 0 -100.00
2012-09-10 2012-09-07 4 HOLX HOLOGIC INC
Common Stock
S - Sale -7,800 57,169 -12.01 20.15 -157,170 1,151,955
2012-09-10 2012-09-07 4 HOLX HOLOGIC INC
Common Stock
M - Exercise 7,800 64,969 13.64 18.32 142,896 1,190,232
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
M - Exercise -5,456 0 -100.00
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
M - Exercise -40,564 7,800 -83.87
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Common Stock
S - Sale -5,456 57,169 -8.71 20.17 -110,048 1,153,099
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Common Stock
M - Exercise 5,456 62,625 9.54 18.32 99,954 1,147,290
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Common Stock
S - Sale -40,564 57,169 -41.50 20.15 -817,365 1,151,955
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Common Stock
M - Exercise 40,564 97,733 70.95 18.32 743,132 1,790,469
2012-09-07 2012-09-06 4 HOLX HOLOGIC INC
Common Stock
S - Sale -17,200 57,169 -23.13 20.19 -347,268 1,154,242
2012-01-10 2012-01-06 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
M - Exercise -36,850 0 -100.00
2012-01-10 2012-01-06 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
M - Exercise -5,416 0 -100.00
2012-01-10 2012-01-06 4 HOLX HOLOGIC INC
Common Stock
S - Sale X -36,850 74,369 -33.13 18.53 -682,830 1,378,058
2012-01-10 2012-01-06 4 HOLX HOLOGIC INC
Common Stock
M - Exercise 36,850 111,219 49.55 18.46 680,435 2,053,659
2012-01-10 2012-01-06 4 HOLX HOLOGIC INC
Common Stock
S - Sale X -5,416 74,369 -6.79 18.53 -100,358 1,378,058
2012-01-10 2012-01-06 4 HOLX HOLOGIC INC
Common Stock
M - Exercise 5,416 79,785 7.28 18.46 100,006 1,473,230
2010-01-29 3 HOLX HOLOGIC INC
Common Stock
39,184
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)